It is well established that the risk of cancer differs among LS patients based on the germline-altered MMR gene (MLH1, MSH2, MSH6, or PMS2), implying that quality of colonoscopy, surveillance intervals, treatment, and preventive strategies may differ between LS subgroups [33]. This evidence concerns the gene MSH2 and cancer.